
IS THE “PROSTATE CANCER” LABEL FOR GLEASON 6 DOING MORE HARM THAN GOOD?
This has become one of the biggest debates in prostate cancer care.
In this clip, Scott Eggener, MD discusses why some experts believe certain low-risk Gleason 6 prostate cancers may eventually need a different name.
As Dr. Eggener explains, many men hear the word “cancer” and immediately assume the worst, even when certain low-risk prostate cancers may never spread, cause symptoms, or shorten life expectancy.
That psychological burden can sometimes become severe. In this clip, Dr. Eggener discusses research showing that men diagnosed with Gleason 6 prostate cancer have a measurably higher rate of suicide compared to the general population, despite many of these cancers being considered very low risk.
At the same time, other experts worry that changing the name could confuse patients or cause some men to stop following up appropriately with Active Surveillance.
Active Surveillance is a management approach where certain low-risk prostate cancers are carefully monitored over time with PSA testing, imaging, and follow-up appointments rather than immediate treatment.
Dr. Eggener was at University of Chicago at the time this interview was recorded and now serves as Chair of Urology at UCLA Health.
If you or someone you love has been diagnosed with low-risk prostate cancer, talk with a qualified urologist about your specific situation and management options.
And for men who have never discussed prostate cancer screening, ask your doctor whether PSA testing may be appropriate based on your age, family history, symptoms, and overall risk factors.
What are your thoughts on this debate?
Educational only. Not medical advice.
English



